Current and emerging medications for the management of obesity in adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Walmsley R;Walmsley R; Sumithran P; Sumithran P; Sumithran P
  • Source:
    The Medical journal of Australia [Med J Aust] 2023 Aug 21; Vol. 219 (4), pp. 188. Date of Electronic Publication: 2023 Jul 04.
  • Publication Type:
    Letter; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Australasian Medical Publishing Co Country of Publication: Australia NLM ID: 0400714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1326-5377 (Electronic) Linking ISSN: 0025729X NLM ISO Abbreviation: Med J Aust Subsets: MEDLINE
    • Publication Information:
      Publication: : Pyrmont, NSW : Australasian Medical Publishing Co.
      Original Publication: Sydney : Australasian Medical Pub. Co.
    • Subject Terms:
      Obesity*/drug therapy ; Diabetes Mellitus, Type 2*/drug therapy; Adult ; Humans
    • References:
      Inglis JM, Kichenadasse G, Mangoni AA. Current and emerging medications for the management of obesity in adults [letter]. Med J Aust 2023; 219: 187-188.
      Walmsley R, Sumithran P. Current and emerging medications for the management of obesity in adults. Med J Aust 2023; 218: 276-283. https://www.mja.com.au/journal/2023/218/6/current-and-emerging-medications-management-obesity-adults.
      Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023; 46: 384-390.
      Thompson CA, Stürmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care 2022; 46: 249-251.
      Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995-2015). J Natl Cancer Inst 2020; 112: 810-817.
      Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473-1486.
      Sattar N, Lee M, Kristensen S, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diab Endocrinol 2021; 9: 653-662.
    • Grant Information:
      1178482 National Health and Medical Research Council
    • Contributed Indexing:
      Keywords: Cancer; Diabetes mellitus, type 2; Obesity; Pharmaceuticals; adverse events; endocrine system neoplasms
    • Publication Date:
      Date Created: 20230704 Date Completed: 20230822 Latest Revision: 20230919
    • Publication Date:
      20240628
    • Accession Number:
      10.5694/mja2.52031
    • Accession Number:
      37402483